TABLE 2

Cell-based clinical trials ( MSC, MSC derivatives and other cells)

Clinical trials based on MSCs
Date of registration/ Execution timeStudy phase/Recruitment statusID/URLTitleCell typeNumber of total particpants/ Intervention or treatment
160
14–02-2020/20-02-2020 to 20-02-20210/Not RecruitingChiCTR2000029816/http://www.chictr.org.cn/ showproj.aspx?proj=49389Clinical Study for Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID- 19)UCB- MSCs; UCB-NKExperimental group:
Conventional treatment followed by iv infusion UCB- MSCs
Control group: Conventional treatment
260
14-02-2020/20-02-2020 to 20-02-20210/ Not RecruitingChiCTR2000029817/http://www.chictr.org.cn/ showproj.aspx?proj=49384Clinical Study of Cord Blood NK Cells Combined with Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID- 19)NK and UCB- MSCsExperimental group:High dose group: High-dose NK cells (>5×109) and MSCs (>5×109), iv infusion once, every 2 days for a total of 5 times
Conventional dose group:
Conventional dose NK cells (>3×109) and MSCs (>3×109), iv infusion once every 2 days for a total of 3 times Preventive dose group:
Preventive dose NK cells (>3×109) and MSCs (>3×109), iv infusion once every week for a total of 1
time.
363
07-02-2020/15-01-2020 to 31-12-20220/ RecruitingChiCTR2000029606/http://www.chictr.org.cn/ showproj.aspx?proj=49146Clinical Study for Human Menstrual Blood-Derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)MenSCsExperimental group A:
1. Conventional treatment followed by iv infusion of MenSCs. Control group A:
Conventional treatment
Experimental group B:
1: Artificial liver therapy+conventional treatment
2: Artificial liver therapy followed by iv infusion of MenSCs +conventional treatment Control group A: Conventional treatment
410
07-02-2020/06-02-2020 to 30-09-20202/ RecruitingNCT04269525/https://clinicaltrials.gov/ show/NCT04269525Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) PneumoniaUC- MSCsExperimental group:
UC-MSCs 3.3×107 cells/50 mL/bag, 3 bags each time. And UC-MSCs will be infused iv on the 1st, 3rd, 5th, and 7th days after enrollment, 1 time each day. Control group: None specified
570
05-02-2020/31-01-2020 to 31-12-20200/ RecruitingChiCTR2000029580/http://www.chictr.org.cn/ showproj.aspx?proj=49088A prospective, single-blind, randomized controlled trial for Ruxolitinib combined with mesenchymal stem cell infusion in the treatment of patients with severe 2019-nCoV pneumonia
(novel coronavirus pneumonia, NCP)		MSCsExperimental group:
Ruxolitinib combined with MSCs.
Control group: Routine treatment.
620
27-01-2020/21-01-2020 to 00-12 20211/RecruitingNCT04252118/https://clinicaltrials.gov/ show/NCT04252118Mesenchymal Stem Cell
Treatment for Pneumonia Patients
Infected With 2019 Novel Coronavirus		MSCsExperimental group:
3.0×107 MSCs iv at day 0, day 3, day 6
Control group: None specified
748
14-02-2020/16-02-2020 to 15-02-2022NA/Not recruitingNCT04273646/https://clinicaltrials.gov/ ct2/show/NCT04273646Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe PneumoniaUC- MSCsExperimental group:
4 times of UC-MSCs (0.5×106 UC-MSCs·kg−1 body weight iv at day 1, day 3, day 5, day 7)
Control group: None specified
89
28-02-2020/19-02-2020 to 20-02-20211/ RecruitingChiCTR2000030300/http://www.chictr.org.cn/ showprojen.aspx?proj=50022Umbilical cord mesenchymal stem cells (hucMSCs) in the treatment of high risk novel coronavirus pneumonia (COVID-19) patientsUC- MSCsExperimental group: MSCs
Control group: None specified
932
26-02-2020/14-02-2020 to 31-05-2020NA/Not recruitingChiCTR2000030224/http://www.chictr.org.cn/ showprojen.aspx?proj=49968Clinical study of mesenchymal stem cells in treating severe novel coronavirus pneumonia (COVID- 19)MSCsExperimental group 1:
critical group Intervention, injecting MSCs Experimental group 2:
severe group, Intervention, injecting MSCs
Control group 3:
Control of the critical group, intervention, injecting normal saline Control group 4:
Control of the severe group, intervention, injecting normal saline
1060
24-02-2020/17-02-2020 to 17-04-20200/Not recruitingChiCTR2000030173/http://www.chictr.org.cn/ showprojen.aspx?proj=49229Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstrationUC- MSCsExperimental group: UC-MSCs
Control group: Convention treatment
1160
24-02-2020/24-02-2020 to 31-05-20202/Not recruitingChiCTR2000030138/http://www.chictr.org.cn/ showproj.aspx?proj=50004Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID- 19)UC- MSCsExperimental group:
Iv injection of UC-MSCs
Control group:
Routine treatment+placebo
1216
23-02-2020/01-02-2020 to 31-08-2020NA/ RecruitingChiCTR2000030116/http://www.chictr.org.cn/ showproj.aspx?proj=49901Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19)UC- MSCsExperimental group: Different stem cell doses
Control group: None specified
1340
22-02-2020/01-03-2020 to 31-12-20210/Not recruitingChiCTR2000030088/http://www.chictr.org.cn/ showproj.aspx?proj=49902Umbilical cord Wharton's Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID- 19)UC-Whartons Jellys MSCsExperimental group:
Iv injection of Wharton's Jelly MSCs (1×106/kg), cell suspension volume: 40 mL
Control group: Iv 40 mL saline
1420
20-02-2020/06-02-2020 to 05-02-2022NA/ RecruitingChiCTR2000030020/http://www.chictr.org.cn/ showproj.aspx?proj=49812The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID- 19)MSCsExperimental group:
Case series: MSCs therapy
Control group:
None specified
15120
18-02-2020/30-01-2020 to 31-03-20201-2/RecruitingChiCTR2000029990/http://www.chictr.org.cn/sho wproj.aspx?proj=49674Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus pneumonia (COVID- 19)MSCsExperimental group: MSCs
Control group: Saline
1645
28-02-2020/28-02-2020 to 31-12-20211-2/Not recruitingNCT04288102/https://clinicaltrials.gov/ct2/ show/NCT04288102Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19)MSCsExperimental group: 3 times of MSCs ((body weight≥70 kg, 4.0×107 cells per time; body weight <70 kg, 3.0×107 cells per time) iv at day 0, day 3, day 6).
Control group:
Saline containing 1% human serum albumin (solution of MSCs）3 times of placebo（iv at day 0, day 3, day 6）
1748
24-02-2020/24-02-2020 to 01-02-2021NA/ RecruitingNCT04293692/https://clinicaltrials.gov/ show/NCT04293692Therapy for Pneumonia Patients Infected by 2019 Novel CoronavirusUC- MSCsExperimental group:
Participants will receive conventional treatment plus 4 times of 0.5×106 UC-MSCs·kg−1 body weight suspended in 100 mL saline containing 1% human albumin iv, at day 1, day 3, day 5, day 7. Control group:
Participants will receive conventional treatment plus 4 times of placebo (100 mL saline containing 1% human
albumin) iv at day 1, day 3, day 5, day 7.
Clinical trials based on MSCs-derivatives
Date of registration/ Execution timeStudy phase/ Recruitment statusID/ URLTitleCell typeNumber of total participants/ Intervention or treatment
130
04-02-2020 /5-02-2020 to 30-04-20210/ Not
Recruiting		ChiCTR2000029569/http://www.chictr.org.cn/ showproj.aspx?proj=49062Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled trialUC- MSCs CMExperimental group:
Conventional treatment combined with UC-MSCs CM
Control group: Conventional treatment
230
19-02-2020/15-02-2020 to 31-07-20201/ Not RecruitingNCT04276987/https://clinicaltrials.gov/ct2/ show/NCT04276987A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus PneumoniaAT- MSCsExoExperimental group: 5 times aerosol inhalation of MSCs-derived exosomes (2.0×108 nano vesicles/3  mL at day 1, day 2, day 3, day 4, day 5). Control group: None specified
326
2020-02-26/28-02-2020 to 31-05-20200/ Not RecruitingChiCTR2000030261/http://www.chictr.org.cn/ showprojen.aspx?proj=49963A study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of novel coronavirus pneumonia (COVID-19)MSCs ExoExperimental group:
Aerosol inhalation of exosomes
Control group: Blank
490
03-03-2020/31-01-2020 to 31-01-2021NA/ Not RecruitingChiCTR2000030484/http://www.chictr.org.cn/ showproj.aspx?proj=50263HUMSCs and Exosomes Treating Patients with Lung Injury following Novel Coronavirus Pneumonia (COVID-19)UC- MSCs and ExoExperimental group:
Group 1: HUMSCs iv, 5×107 cells/ time, once / week, twice/course
Group 2:
HUMSCs iv infusion, 5×107 cells / time, 1 time / week, 2 times / course, a total of 2 courses; Exosomes: iv
administration, 180 mg / time, 1 time / day, 7 days / course, 2 courses in total
Control group:
Same amount of placebo (stem cell solvent)
Clinical trials based on other cell types
Date of registration/ Execution timeStudy phase/ Recruitment statusID/ URLTitleCell typeNumber of participants/ Intervention or treatment
160
14-02-2020 /20-02-2020 to 20-02-20210 / Not RecruitingChiCTR2000029812/http://www.chictr.org.cn/ showproj.aspx?proj=49374Clinical Study for Umbilical Cord Blood Mononuclear Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID- 19)UCBMCExperimental group:
Conventional treatment followed by iv of UCBMC preparations
Control group: Conventional treatment
230
05-02-2020 /05-02-2020 to 30-04-20210 / RecruitingChiCTR2000029572/http://www.chictr.org.cn/ showproj.aspx?proj=41760Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled clinical trialUCBMCExperimental group:
Conventional treatment combined with UCBMC
Control group: Conventional treatment
3100
17-02-2020 /24-02-2020 to 31-12-20241-2 /RecruitingNCT04276896/https://clinicaltrials.gov/ show/NCT04276896Function and Safety Study of SARS-CoV-2 Synthetic Minigene Vaccinesautologo us LV- DC vaccine or antigen- specific cytotoxic T CellsExperimental group:
Patients will receive approximately 5×106 LV-DC vaccine or 1×108 CTLs as a single infusion via sub- cutaneous fluids / Iv injection and may receive additional infusions.
Control group: None specified
430
13-02-2020 /20-02-2020 to 30-12-20201 / RecruitingNCT04280224/https://clinicaltrials.gov/ show/NCT04280224NK Cells Treatment for Novel Coronavirus PneumoniaNK cellsExperimental group:
Conventional treatment plus twice a week of NK cells (0.1-2×107 NK cells·kg−1 body weight) Control group: Conventional treatment
520
06-03-2020/10-04-2020 to 10-11- 20202 /Not recruitingNCT04299152/https://clinicaltrials.gov/ct2/s how/NCT04299152Clinical Application of Stem Cell Educator Therapy for the Treatment of Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)CB-SCExperimental group:
Combination Product: Stem Cell Educator-Treated Mononuclear Cells Apheresis SCE therapy circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SC in vitro, and returns the “educated” autologous immune cells to the patient's circulation.
Control group:
Conventional treatment of patients with SARS-CoV-2. Patients will receive the regular treatments by only addressing their symptoms such as reducing fever and cough.
690
28-02-2020 /01-03-2020 to 17-02-20210 /Not recruitingChiCTR2000030088/http://www.chictr.org.cn/ showproj.aspx?proj=49779Clinical trial for umbilical cord blood CIK and NK cells in the treatment of mild and general patients infected with novel coronavirus pneumonia (COVID- 19)CIK and NKExperimental group:
CIK group: UCB CIK cells (1.6×108/kg) were injected twice every other day.
NK group: UCB NK cells (1.6×108/kg) were injected twice every other day.
Control group:
Conventional therapy

CB-MSCs: Umbilical cord blood derived-mesenchymal stem cells; UCB-NK: Umbilical cord blood derived-natural killer; MenSCs: mesenchymal stem cells derived from menstrual uid; UC-MSCs: umbilical cord derived mesenchymal stem cells; UC-MSCs CM: umbilical cord derived mesenchymal stem cells-conditioned médium; AT-MSCs Exo: Adipose tissue xosomes; MSCs Exo: mesenchymal stem cells exosomes; UCBMC: umbilical cord blood derived mononuclear cells; CTL: cytotoxic T cells; LV: lentivirus; DC: dendritic cells; NK: atural killer cells; CB-SC: cord blood stem cells; CIK: Cytokine-induced killer cells; Iv: intravenous.